|Day Low/High||2.88 / 3.14|
|52 Wk Low/High||2.48 / 21.00|
Insiders at these companies have been scooping up shares of their own stock lately.
Shares of aTyr Pharma (LIFE) are climbing late Tuesday afternoon as BMO Capital began coverage of the stock with a ‘market perform’ rating and $8 price target.
These stocks look ready to break out and trade higher from current levels.
Data for Phase 1b/2 Clinical Trial of Resolaris in Adult FSHD Patients Expected at Approximately the End of First Quarter 2016
aTyr Sponsored Research For New Target For Rare Hereditary Peripheral Neuropathies
Physiocrine-Based Therapy Harnesses Natural Immunomodulation Pathway to Address Rare Genetic Muscular Dystrophy